摘要
重症心力衰竭患者的交感神经活化的作用比较重要,卡维地洛属于非选择性的第三代β-受体阻滞剂,并且其还兼有选择性的阻断α1受体,同时具备保护肝肾功能、抗氧化损伤和抗自由基等作用.高浓度的卡维地洛可阻滞钙的通道,并在调节患者的代谢紊乱、阻滞患者的平滑肌细胞增殖等方面具备显著作用,这个作用是其他β-受体阻滞剂不具备的功能.本研究在分析卡维地洛的药代动力学和药理学的基础上,综述卡维地洛治疗重症心力衰竭患者的临床研究进展.
Sympathetic activation plays an important role in patients with severe heart failure. Carvedilol belongs to nonselective beta blockers of third generation,and it also has selective blocking alpha 1 receptor,along with the protection of liver and kidney function,anti-oxidant damage and antifree radical effect.Carvedilol with high concentration can block calcium channels,adjust metabolic disorders,and block smooth muscle cell proliferation in patients,which is not available in other blockers. Based on the analysis of the pharmacokinetics and pharmacology of carvedilol,the study summarized the clinical research progress and new research situation of carvedilol in the treatment of severe heart failure patients.
出处
《转化医学电子杂志》
2016年第5期67-68,共2页
E-Journal of Translational Medicine
关键词
卡维地洛
重症心力衰竭
研究进展
carvedilol
severe heart failure
research progress
